Abstracts tagged "lupus nephritis and systemic lupus erythematosus (SLE)"

Abstract Number: 2892 • 2013 ACR/ARHP Annual Meeting
Masp-1/3 Deficient MRL/Lpr Mice Lack The Alternative Complement Pathway Activation and Are Protected From Development Of Lupus-Like Glomerulonephritis
Takeshi Machida¹, Natsumi Sakamoto¹, Teizo Fujita¹, Minoru Takahashi² and Hideharu Sekine¹, ¹Immunology, Fukushima Medical University School of Medicine, Fukushima, Japan, ²Department of Immunology, Fukushima Medical University School of Medicine, Fukushima, Japan
Background/Purpose: Complement has both protective and pathogenic functions in lupus due to a balance between its role in the clearance of immune complexes (ICs) and…
Abstract Number: 1071 • 2013 ACR/ARHP Annual Meeting
Prevalence Of Systemic Lupus Erythematosus and Lupus Nephritis In The United States: Analysis Of Commercial and Public Insurance Billing Data
Kunal Gandhi¹, Evo Alemao¹, Hugh Kawabata¹ and Jan L. Hillson², ¹Bristol-Myers Squibb, Princeton, NJ, ²Bristol-Myers Squibb, Seattle, WA
Background/Purpose: Prevalence estimates of Systemic Lupus Erythematosus (SLE) in the U.S. vary, with numbers ranging from 161,000 (Helmick, 2008) to 1.5 million (Lupus Foundation of…
Abstract Number: 884 • 2013 ACR/ARHP Annual Meeting
Treatment Of Lupus Nephritis With Abatacept Plus Low-Dose Pulse Cyclophosphamide Followed By Azathioprine (the Euro-Lupus Regimen): Twenty-Four Week Data From a Double-Blind Controlled Trial
David Wofsy¹, Anca Askanase², Patricia C. Cagnoli³, W. Winn Chatham⁴, Gabriel Contreras⁵, Maria Dall'era⁶, Mary Anne Dooley⁷, Hilda Fragoso-Loyo⁸, David R. Karp⁹, Meenakshi Jolly¹⁰, Kenneth Kalunian¹¹, Diane L. Kamen¹², Iris Lee¹³, Marc C. Levesque¹⁴, S. Sam Lim¹⁵, Meggan Mackay¹⁶, Cesar Ramos-Remus¹⁷, Brad H. Rovin¹⁸, Tammy O. Utset¹⁹, Swamy Venuturupalli²⁰, Robert Winchester²¹, Linna Ding²², Wendy Gao²², Lynette Keyes-Elstein²³ and Patti Tosta²⁴, ¹Rheumatology/Immunology, University of California San Francisco and NIAID Autoimmunity Centers of Excellence, San Francisco, CA, ²NYU School of Medicine, New York, NY, ³Int Med/Div of Rheum, University of Michigan Health, Ann Arbor, MI, ⁴University of Alabama at Birmingham, Birmingham, AL, ⁵University of Miami, Miami, FL, ⁶Medicine/Rheumatology, University of California, San Francisco, San Francisco, CA, ⁷University of North Carolina at Chapel Hill, Chapel Hill, NC, ⁸Immunology and Rheumatology, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico, Mexico, ⁹Rheumatic Diseases Division, UT Southwestern Medical Center, Dallas, TX, ¹⁰Rheumatology, Rush University Medical Center, Chicago, IL, ¹¹UCSD School of Medicine, La Jolla, CA, ¹²Department of Medicine, Division of Rheumatology, Medical University of South Carolina, Charleston, SC, ¹³Nephrology, Temple University, Philadelphia, PA, ¹⁴Division of Rheumatology and Clinical Immunology, University of Pittsburgh, Pittsburgh, PA, ¹⁵Emory University School of Medicine, Division of Rheumatology, Atlanta, GA, ¹⁶Autoimmune & Musculoskeletal Disease, Feinstein Institute for Medical Research, Manhasset, NY, ¹⁷Unidad de Investigacion en Enfermedades Cronico-Degenerativas, Guadalajara, Mexico, ¹⁸Division of Nephrology, Ohio State University Medical Center, Columbus, OH, ¹⁹Rheumatology, University of Chicago Medical Center, Chicago, IL, ²⁰Cedars-Sinai Medical Center, West Hollywood, CA, ²¹Dept of Medicine & Pathology, Columbia University, New York, NY, ²²NIAID, Bethesda, MD, ²³Rho Federal Systems, Inc., Chapel Hill, NC, ²⁴Immune Tolerance Network, San Francisco, CA
Background/Purpose: Studies in murine models for SLE have shown that CTLA4Ig can ameliorate murine lupus nephritis. Moreover, the combination of CTLA4Ig plus intravenous cyclophosphamide (IVC)…
Abstract Number: 606 • 2013 ACR/ARHP Annual Meeting
Characteristics Of Lupus Nephritis: Data From a Large Multicenter Registry Of Patients With Systemic Lupus Erythematosus
Diane L. Kamen¹, Graciela S. Alarcon², Jill P. Buyon³, Mary Anne Dooley⁴, Richard A. Furie⁵, David S. Pisetsky⁶ and Tammy O. Utset⁷, ¹Department of Medicine, Division of Rheumatology, Medical University of South Carolina, Charleston, SC, ²Medicine, Department of Medicine, University of Alabama at Birmingham, Birmingham, AL, ³Medicine, Division of Rheumatology, NYU School of Medicine, New York, NY, ⁴University of North Carolina at Chapel Hill, Chapel Hill, NC, ⁵The Feinstein Institute for Medical Research and North Shore-Long Island Jewish Health System, Lake Success, NY, ⁶Department of Medicine, Duke University Medical Center, Durham, NC, ⁷Rheumatology, University of Chicago Medical Center, Chicago, IL
Background/Purpose: Renal disease is strongly associated with morbidity and mortality among SLE patients. We utilized the Lupus Clinical Trials Consortium, Inc. longitudinal registry of SLE…
Abstract Number: 661 • 2012 ACR/ARHP Annual Meeting
Co-Localization of C-Reactive Protein, Immunoglobulin G and Complement in Renal Subendothelial Immune Deposits of Proliferative Lupus Nephritis Detected Using Immunogold Electron Microscopy
Christopher Sjöwall¹, Anders I. Olin², Thomas Skogh³, Jonas Wetterö⁴, Mattias Mörgelin², Ola Nived⁵, Gunnar Sturfelt⁶ and Anders A. Bengtsson⁷, ¹Deparment of clinical and experimental medicine, Linkoping University, Linkoping, Sweden, ²Infection Medicine, Department of Clinical Sciences, Lund University, Lund, Sweden, Lund, Sweden, ³Deparment of clinical and experimental medicine, Linköping University, Linköping, Sweden, ⁴Department of Clinical and Experimental Medicine, Linköping University, Linköping, Sweden, ⁵Department of Rheumatology, University Hospital Lund, Lund, Sweden, ⁶Department of Clinical Sciences Lund, Section of Rheumatology, Lund University, Lund, Sweden, ⁷Department of Clinical Sciences, Section of Rheumatology, Lund University, Lund, Sweden
Background/Purpose: The pattern recognition molecules C-reactive protein (CRP) and complement protein 1q (C1q) are pivotal parts of the innate immune system and display relevant biological…
Abstract Number: 2500 • 2012 ACR/ARHP Annual Meeting
Podocyte Injury in Membranous and Proliferative Lupus Nephritis: Distinct Underlying Mechanisms?
Gabriela M. Rezende¹, Vilma S. T. Viana¹, Denise M. Malheiros², Elaine P. Leon³, Eduardo F. Borba¹, Neila AS Silva², Irene L. Noronha⁴, Cleonice Silva⁴ and Eloisa Bonfá⁵, ¹Internal Medicine, Division of Rheumatology - Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil, ²Division of AnatomoPathology - Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil, ³Rheumatology, Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil, ⁴Internal Medicine, Division of Nephrology - Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil, ⁵Division of Rheumatology, Faculdade de Medicina, Universidade de São Paulo, São Paulo, Brazil
Background/Purpose: Lupus nephritis (LN) is a major cause of morbidity and mortality in patients with systemic lupus erythematosus (SLE) with proteinuria being the predominant common…
Abstract Number: 2242 • 2012 ACR/ARHP Annual Meeting
Clinical Manifestations and Predictive Factors for Response to Induction Therapy and Maintenance of Remission in ISN/RPS Class V Lupus Nephritis
Masanori Hanaoka, Takahisa Gono, Yasushi Kawaguchi, Hirotaka Kaneko, Kae Takagi, Hisae Ichida, Yasuhiro Katsumata, Yuko Okamoto, Yuko Ota, Sayuri Kataoka and Hisashi Yamanaka, Institute of Rheumatology, Tokyo Women's Medical University, Tokyo, Japan
Background/Purpose: The pathophysiology and the content of treatment differ between International Society of Nephrology/Renal Pathology Society (ISN/RPS) class III/IV lupus nephritis (LN) and class V…
Abstract Number: 1442 • 2012 ACR/ARHP Annual Meeting
IRF-1 Deficient Lupus-Prone MRL/Lpr Mice Show Reduced Glomerulonephritis but Develop Severe Interstitial Nephritis, Renal Vasculitis and Pulmonary Granulomas with Propensity for Th2 Polarity
Hidemaru Sekine¹, Takeshi Machida¹, Natsumi Sakamoto¹, Eiji Suzuki², Xian Zhang³, Christopher Reilly⁴ and Gary S. Gilkeson⁵, ¹Immunology, Fukushima Medical University School of Medicine, Fukushima, Japan, ²Medicine, Medical University of South Carolina, Charleston, SC, ³Medicine, Medical University of South Carolina and Ralph H. Johnson VA Medical Center, Charleston, SC, ⁴Virginia Tech, Blacksburg, VA, ⁵Department of Medicine, Division of Rheumatology, Medical University of South Carolina, Charleston, SC
Background/Purpose: The transcription factor interferon regulatory factor-4 (IRF-4) and -1 (IRF-1) are members of the IRF family of transcription regulators and involved in the development…
Abstract Number: 1055 • 2012 ACR/ARHP Annual Meeting
Sec61 Is Indispensable for Antigen Cross-Presentation and the Development of Lupus Nephritis: A Novel ‘Self-Organized Criticality Theory’ Explaining the Cause of Systemic Lupus Erythematosus (SLE)
Ken Tsumiyama and Shunichi Shiozawa, Department of Medicine, Kyushu University Beppu Hospital, Beppu, Japan
Background/Purpose: We found that systemic lupus erythematosus (SLE) was induced experimentally by repeatedly immunizing the mice normally not prone to autoimmune diseases by any exogenous…
Abstract Number: 885 • 2012 ACR/ARHP Annual Meeting
Interferon α and Self-Organized Criticality Theory
Shunichi Shiozawa¹, Yumi Miyazaki² and Ken Tsumiyama³, ¹Department of Medicine, Kyushu University Beppu Hospital, Beppu, Japan, ²Kyushu University Beppu Hospital/ Kobe University Graduate School of Health Sciences, Beppu/ Kobe, Japan, ³Department of Rheumatology, Kyushu University Beppu Hospital, Beppu, Japan
Background/Purpose: One of the biggest obstacle we face in elucidating the pathogenesis of autoimmunity today is the mechanism how autoreactive lymphocyte clones could survive or…
Abstract Number: 838 • 2012 ACR/ARHP Annual Meeting
Association of Urinary and Serum Soluble Fn14 Levels and TWEAK Levels with Lupus Nephritis Disease Activity
Irene Blanco¹, Ping Wu², Timothy S. Zheng³, Shawn Weng⁴, Jennifer S. Michaelson², Linda C. Burkly² and Chaim Putterman⁵, ¹Rheumatology, Albert Einstein College of Medicine, Bronx, NY, ²Biogen Idec, Cambridge, MA, ³R&D - Rheumatology/Immunology, Biogen Idec Inc, Cambridge, MA, ⁴Biogen Idec, Inc., Cambridge, MA, ⁵Division of Rheumatology, Albert Einstein College of Medicine, Bronx, NY
Background/Purpose: We have showed that the cytokine TWEAK is a biomarker for lupus nephritis (LN). However, soluble receptors for key immune pathways are also potential…
Abstract Number: 839 • 2012 ACR/ARHP Annual Meeting
Urinary Levels of High Mobility Group Box 1 Protein Are Elevated in Patients with Active Lupus Nephritis, and Correlate with Renal Histopathology
Irene Blanco¹, Neelakshi Jog², Chaim Putterman³, Iris Lee⁴ and Roberto Caricchio⁵, ¹Rheumatology, Albert Einstein College of Medicine, Bronx, NY, ²Rheumatology, Temple University, Philadelphia, PA, ³Division of Rheumatology, Albert Einstein College of Medicine, Bronx, NY, ⁴Nephrology, Temple University, Philadelphia, PA, ⁵Medicine/Rheumatology, Temple University, Philadelphia, PA
Background/Purpose: High mobility group box 1 protein (HMGB-1) had been implicated in the pathogenesis of SLE and potentially lupus nephritis (LN). There is increased expression…
Abstract Number: 840 • 2012 ACR/ARHP Annual Meeting
Do Serum Hepcidin 25 Levels Predict SLE Renal or Non-Renal Flares?
Alexandra Friedman¹, Nicholas Young², Paul Jensen³, Xiaolin Zhang⁴, Wael N. Jarjour⁵, Brad H. Rovin⁴, Daniel Birmingham³, Lee Hebert³ and Stacy P. Ardoin⁶, ¹Immunology and Rheumatology, The Ohio State University Wexner Medical Center, Columbus, OH, ²Immunology and Rheumatology, The Ohio State University Medical Center, Columbus, OH, ³Medicine, Ohio State University Medical Center, Columbus, OH, ⁴Division of Nephrology, Ohio State University Medical Center, Columbus, OH, ⁵Dept of Rheumatology/Medicine, The Ohio State University Wexner Medical Center, Columbus, OH, ⁶Pediatric & Adult Rheumatology, Ohio State University College of Medicine, Columbus, OH
Background/Purpose: Biomarkers are needed which can accurately predict systemic lupus erythematosus (SLE) flare, allowing tailoring of immunosuppressive therapy to minimize disease damage and medication toxicity.…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].